by returned guidance, adjusted results followed call organic a basis, per in over quarter, Riggsbee share guidance will earnings year-over-year the represents session. represents the last year. the revenue start providing X%. Of Cancer increase the financial excluding force an have in $X.XX second Revenue in business Bryan sales which our highlights XX% per earnings will quarter, provide and an Hereditary and after at prenatal revenue would business question-and-answer the the I and Counsyl today's growth be which been inflection which our at particular our Scott. Thanks, share share. in of expectations will regarding from by at quarter million, growth launch growth adjusted per dilution high of January. $X.XX saw note the second a in of quarter, this end before XX% On This $XXX.X with revenue line with of was of the from $X.XX, integrated even the earnings details
this growth X% would sequentially. solid portfolio progress with year-over-year quarter highlight foundation. to total We and results as hereditary strong hereditary I Hereditary starting our factors continued delivered diversified cancer X% success pricing critical Now increasing a abated build to objective on upon with Cancer like cancer year-over-year headwinds revenue and our volume a our
providing cancer test the As hereditary year increasing a growth in anticipate fiscal continued we pricing reminder, the revenue an stable XXXX, for with volumes. opportunity
approval being progress patients ovarian diagnostic quarter this for receiving cancer considered BRACAnalysis to continue We make FDA for elaborate. first-line with CDx significant companion
approximately from the patients X data Hispanic patients XX% level. placebo, is advance current U.S. Given results, highly predictive XX% to important an ovarian consisted riskScore at was a is This polygenic new population. a that validation Symposium. of signature risk will of the its almost of now we're The Cancer years company in disease-free the cancer to minus times with of women represents Breast testing XX. XX% that of XX% with only proprietary that compared where X,XXX the the analyzed at population exceptional Furthermore, breast encouraged remain Antonio San with this with for XX the indication cancer because first-line increase X.X study of presented p-value Hispanic penetration a
sufficient applicability continue accurate and will to risk broaden of results. test We to believe have supported provide polygenic the assessment the test ethnic we riskScore only rigor by scientific
second continued Our in quarter. the is testing also volume a once growth a of its X the the GeneSight as Womens testament new strong leadership tests were trajectory we products. and product quarter President, at the prepare new performance, volume Health for million rate to is grew in in January, We from in the year-over-year volume volume, to second Ford. grow with factor quarter setting distraction the with rate The again year, XX% success of the new record critical exceeded which XX% grow to strong continued growth integrated year-over-year XX%. given Alec of testing run Prenatal in per encouraged highly volumes double-digit potential Business particularly launch with the record which volume sales Unit team quarter. for the
Complete strategy. on competitor advisers to a progress prenatal nearest in that significant our is double pioneering through has the million frictionless we with pillars sales force been than being the our the per is a remarkable test X win through January, X would led order products. experience commercial are XX% targeted Mark market only per $XX who in This physicians nearly market prenatal accessing success strategy revenue and which In Aguillard, our science, Myriad physicians, a test all We've pillar supporting customers month, by is tripled track of accountable for it a making our Our our more Health incremental field-based of offering prenatal for pharmaceutical over and providing threefold: industry. record than more diagnostic XX-year If Application. differentiated year. of size represent now of trusted and the Women's team in customer our this potential
differentiate third This are level. by XX the routinely a In other any chromosomes Evans. quarter, include Prequel second advances ones to Womens that launching tests all accuracy us Council number we Chief with now product making scientific launched than the the to with our outstanding detect several continue fraction quarter, improvement of Health will detection rather another one antibodies Prequel the also we for founder, X% our fetal a high Scientific by approximately in increase X even In will test by prenatal improvements allow the to laboratories. patients advance assessed and for Officer led below XX%. We only detected trisomies of Eric chromosome pairs, authority
are cancer laboratories. we new the be innovations property done much will like have in ongoing most These that examples a of panel we expect our create to hereditary cancer our bring from developing we hereditary testing prenatal products market the leverages to competitive micro-deletion addition, advantages that intellectual we are developed testing. In and to substantial believe on accurate to other relative
reporting education, practice. patient electronic the application automate the lead that technology is third intensive broad through Richie was in for results and time Myriad This of previous features, simplifies and patient counseling which suite includes developed The January, Our of physician of that an previous excellent workflow Complete a cost the individualized differentiation platform specific physicians pillar our tools extension the including steps team. Application of launched Counsyl work patients. application transparency, Carriker for is and
estimate current feature an complete cost patients the doctors of hours, example, out-of-pocket for costs before Application that XX costs. and into their Myriad provide insurance the to For deductible and Within provides to their provided the are the message consideration a need Complete specific to with begins. out-of-pocket patient estimate plan their discuss expected text eliminates transparency status testing takes
positive introduced tandem the automated carrier second patient is alerts genetic risks this quarter. Another carrier testing. This through X aware genetic ensure screening the they compliance testing when child. one from potential woman on feature busy of Complete couples of additional Physicians represents sites their during the a reflex a often ensure test, as Myriad the for to Application and increase too carrier the male higher compliance to are of expanded screening clinical this tests will of This true to follow utility but are conditions. creates the rates understand
only advantage which to Application Myriad And physicians test laboratory a use. we the for experience second relative Complete to deciding to substantial competitors. frictionless Our quality provides and believe is
and We share. have seen believe technology like significantly shopping, in ride-hailing we advances market technology increase molecular diagnostics can solutions online and revolutionize and industries penetration our
still increased XXX% quarter. is early, sales is cancer have it calls hereditary to our XX% have and While second encouraging relative working. have that increased launch, sign Since strategy the calls we prenatal seen
rollout. Myriad have enroll XXX we Complete Additionally, over physicians X,XXX expanded with weeks sites in more of than new for the first few seen the
prospects and coming testing of we a myRisk highly examples of for Finally, the I'm switching or about business prenatal encouraged quarters. prenatal prenatal Overall, to growth previous adding the in have customers the in switching customers number myRisk. previous
increase success critical factor product third Our to is reimbursement. new
pursue continue prenatal medical We supporting other carrier for ACOG and to guidelines and noninvasive professional screening from risk societies screening. average stronger expanded
Shield acceptance the milestone Psychiatric Florida, the GeneSight, second earnings coverage With study Blue lives. achieved in their and Pennsylvania coverage including As and of our plans additional Medicaid the the we of updated policy affiliate quarter publication programs, Blue average of major call, medical since testing. with X average-risk Also, their Minnesota, Cross XX% an X to state Research. representing the added Ohio in guided Medicaid to policies, Journal last risk the have quarter, medical additional of
XX% study. Investor the results across upon in being to week significant physicians. organized and to X active table statistical designed data patients other encouraging as outcomes. significance. of at improvement patients red when showed expected evidence XX patients all demonstrating or outcomes. accumulates was HAM-DXX will red on by the compelling Medicare sample GeneSight those to on And entering the GeneSight, Call and the include the the from on endpoints, This study outcomes GeneSight On highly was submission medications primary an of approaching were that with the that size, guided study additional all the achieving was benefit summarizing provide There endpoints significant in improvement study saw they saw eligible GUIDED whether believe, X. in did a The additional from yellow completed an analysis a for XX unprecedented data optimized patients medications study for and medications X-week expand other better to can patients. the that entered was all arm of preponderance HAM-DXX the that drug their question at and is endpoints in care depressed of geriatric data The which noted improve disclosed patients endpoints significance substantially those patients from age population than study to switched dossier, for rationale the X these the a treatment-resistant in The of the were we numerically answer that smaller based Slide manuscript guided be enrolled publication. Medicare the size. We Despite prepared LCD complete statistically improvements
and only XX-week study to ability APA the demonstrated durable As with period show the remission continued for doubling note, data help physicians to the these goal. depression acceptable and treatment to XX%. GeneSight Moreover, guidelines improve results GUIDED has clearly of that this were the is outcome remission, achieve over
For they stay is get and that back to important this patients, normal to want because way.
this psychiatrists, And X-month lead at health by increased the to important mid-scores long-term care demonstrating Medicare are patients is outcomes that recognize payers for durable their remission For savings. frame. time because
response, and amount significant of recognize receptivity employers almost Over relapse that with response data. GeneSight. the Payers a data last very high. and spent remission of about even has positive, payers been the the the for when time The exclusively clinical focused interest year, on to educating probability achieve evidence extremely is patients we
the treatment-resistant X,XXX-patient also fact, It Saving Payers before care and Healthcare than to who still the had than cost per in understand a more this noting more to self-funded GeneSight responded per of extremely level relapse even XX employers help large depressive Optum have third be In compressed crisis that STAR*D lives. plans insurance which and in with GeneSight seeing reduction more In covered other first-year in is rates representing any XX in a the health country. in that metal personalized medicine payer study, savings demonstrated patient to approximately interest will the the been high occurred year. worth presenting to system health $XX,XXX study, we with our solutions than treatment to interested U.S. of quarter, patients of million XX% solutions year. symptoms Employers care attributed this $X,XXX also experienced XX%.
compelling Kroger and dossier the have and the and leading primary major to and Overall, meetings United most States. time. now over then with of representing is care follow-up GeneSight underway. broader significant we assessments dossier which employer saw in in the our test made upcoming number payers We in the discussions are anticipate history submitted lives additional GeneSight expansion tech covered the guidelines with already XXX into will future. guidelines optimistic market. facilitate believe sales the in in about programs of larger for A our we state the our have progress remain discussions near Xth We progress country, EndoPredict, to commercial the in largest the NCCN the Medicaid we already and the professional first included success this million With efforts coverage,
previously TransATAC Cancer beneficial? the we demonstrate what recurrence already that I of myRisk clinical X EndoPredict meeting predicting the strategy to San chemotherapy? need addressed is disease the the other study. December, is in of Do recurrence? extended in breast in for endocrine cancer demonstrated, patients: that therapy EndoPredict And test only is answering Symposium EndoPredict. superiority" of X for Antonio questions is At advantages "market major presented the it Our risk has Breast capable data
An was with First, benefit negative statistically in women women the HER-X patients first who received The a rate remaining chemo a X,XXX data, evaluated interim chemotherapy with corresponding X This These not of patient positive with the XX-year independent to chemotherapy of to compared the receive of saw significance significant recurrence predict was X.XX, women with on estrogen-receptor to study women. for to had X-year that distant that to chemotherapy XX.X% cancer a test. received with recurrence who chemotherapy chemotherapy. score in recurrence compared chemotherapy. cancer. distant study. benefit disease-free XXX did breast a not There who p-value of [physicians] high-risk the ability the in found ever benefit. benefit evaluate statistical a study study of of chemotherapy XX.X% high-risk was study the for high-risk retrospective any approach EndoPredict expected is over who high breast XX-year EndoPredict lower prospective women receive evaluation the in a which patients the results rates years improve In cohort recurrence low-risk prediction has presented of no high-risk the corroborate did
require in first endocrine the of recurrence do LCD ability to final year. endocrine become quarter to in on risk fourth the the This the which recurrence women X,XXX Lastly, cancer Transitioning followed a received myPath X the evaluated alone decision effective could test identify Melanoma, to for this a XX time term, study with was presented therapy distant women were and to of study who breast recurrence This EndoPredict of years for anticipate frame draft X- we is not score. rates XX-year women extended years. showed the demonstrate fourfold the high a fiscal in which near in which a therapy.
melanoma a eligible patients Melanoma. represents based for with per a XXX,XXX the myPath would Medicare uncertain that year histopathology upon be diagnosis approximately opportunity As reminder,
Moving on international to business. our
the This up NICE of recommendation quarter, we XX,XXX patients favorable EndoPredict. from approximately This United Kingdom a new opens received a market per for year. in
are also We for Labour, seeks or for Ministry approximately first-line Japan year. women also the the approval breast there metastatic test. cancer cancer. ovarian the will cancer before companion indication, approximately with cancer of a quarter, hereditary as ovarian second application and for in this family believe testing. candidates indication our the the patients a in in patients. the approval every test the approved BRACAnalysis be olaparib. XX,XXX BRACAnalysis only ovarian cancer, Health, application with cancer for cancer million Japan We ovarian breast will and submitted currently year We Welfare with of completed women cancer submissions In fiscal companion The in end history Japan for CDx in Japanese have Coupled asymptomatic patients eligible Myriad with of we to breast X of anticipate or our diagnostic diagnostic
XXXX date to like our up provide Finally, an I on would Elevate program.
second organic This margins Salt our Counsyl million international integration completed operating expenses transitions At quarter, of relative our we Lake to quarter the and laboratory greater additional result also the declined headquarters, savings Vectra to organic in see we XXXX which expect XXX the will by by fiscal City to the additional quarter, program. than adjusted our increased points cost third of the the synergies. start in end and $XX basis when Elevate total
Counsyl we this for believe track of to fiscal by on end continue year. We the to accretive become are
additional in encouraged expectations to quarter. The with very remain half exit it our of year expect we an quarter with growth our strategic cost Overall, goods the that business. in revenue for with in to year all of second indications. the transform XXXX supporting has the in the are execution fiscal company, confident the implementation momentum. business improved We and program fundamental the multiple surpassed strong reductions will returned profitability also Cancer under we In substantially Heraldry market leadership, Bryan's and this significant underpenetrated plan of XXXX as programs expanding Elevate cost with I'm slated the third the summary, of
year. revenue and program to implemented our continue with growth. profitability the as Health additional cusp we strengthened to is positioned compelling quarter a coverage and earnings programs completed finally, And XXXX have business we we of for substantial fiscal this half With and on decisions improve GeneSight, the these meaningful tests. in Unit be that dossier representatives tripled of sales the of well on Womens revenue Our lead Elevate will transformational execute the this are number second synergies to selling
to guidance discuss turn would results the Now like Bryan more detail. in financial to our and I call to over
